5LB Stock Overview
A clinical-stage immunotherapeutic company, engages in developing antiviral and anticancer vaccine platforms.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
BioVaxys Technology Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.036 |
| 52 Week High | CA$0.072 |
| 52 Week Low | CA$0.0006 |
| Beta | 0.095 |
| 1 Month Change | -19.78% |
| 3 Month Change | -43.15% |
| 1 Year Change | 157.04% |
| 3 Year Change | -75.42% |
| 5 Year Change | n/a |
| Change since IPO | -86.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5LB | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -18.0% | 4.7% | -0.3% |
| 1Y | 157.0% | -19.6% | 4.5% |
Return vs Industry: 5LB exceeded the German Pharmaceuticals industry which returned -19.4% over the past year.
Return vs Market: 5LB exceeded the German Market which returned 4.3% over the past year.
Price Volatility
| 5LB volatility | |
|---|---|
| 5LB Average Weekly Movement | 45.8% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 5LB's share price has been volatile over the past 3 months.
Volatility Over Time: 5LB's weekly volatility has decreased from 100% to 46% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Chris Passin | biovaxys.com |
BioVaxys Technology Corp., a clinical-stage immunotherapeutic company, engages in developing antiviral and anticancer vaccine platforms. It develops BVX-0320, a SARS-CoV-2 vaccine; BVX-1021, a vaccine for the strain of coronavirus that causes SARS1; and BVX-0918, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, a novel diagnostic platform to identify a T-cell immune response to the presence of SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions.
BioVaxys Technology Corp. Fundamentals Summary
| 5LB fundamental statistics | |
|---|---|
| Market cap | €9.97m |
| Earnings (TTM) | -€8.49m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.2x
P/E RatioIs 5LB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5LB income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$12.57m |
| Earnings | -CA$12.57m |
Last Reported Earnings
Jul 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.06 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 5LB perform over the long term?
See historical performance and comparison